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ABSTRACT 
 
 
Introduction 
Atrial fibrillation/flutter (AF) is the most common arrhythmia in older people. It associates with 
reduced exercise capacity, increased risk of stroke, and mortality. We aimed to determine 
retrospectively whether pravastatin reduces the incidence of AF and whether any electrocardiographic 
measures or clinical conditions might be risk factors for its development. 
 
Methods and Results 
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a randomised, double-
blind controlled trial that recruited 5,804 individuals aged 70-82 years with a history of, or risk factors 
for, vascular disease.  2,891 were allocated to pravastatin and 2,913 to placebo; mean follow-up was 
3.2 years. ECGs, which were recorded at baseline, annually thereafter and at run out, were processed 
by computer and reviewed manually. 
 
264/2912 (9.1%) of the placebo group and 283/2888 (9.8%) of the pravastatin treated group developed 
AF [HR 1.08 (0.92,1.28), p=0.35)].  Multivariate analysis showed that PR and QTc intervals, age, left 
ventricular hypertrophy and ST-T abnormalities were related to development of AF after adjustment 
for many variables including alcohol consumption, which itself was univariately predictive of 
developing AF.   Previous myocardial infarction on the ECG was not a risk factor. A history of 
vascular disease was strongly linked with developing AF but not diabetes and hypertension.  
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Conclusion 
Pravastatin does not reduce the incidence of AF in older people at risk of vascular disease, at least in 
the short-medium term. Risk factors for AF include older age, prolongation of PR or QTc intervals, left 
ventricular hypertrophy and ST-T abnormalities on the ECG.  
 
 
Key words: Atrial fibrillation, ECG, statins, risk factors 
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Introduction. 
 
Atrial fibrillation / flutter (AF) is the most common cardiac arrhythmia and its prevalence varies from 
0.1% in individuals under 55 years of age to 9% in individuals over 80 years of age (1). AF is well 
known to be a risk factor for stroke and indeed all cause mortality (2).  In the recent QRISK2 study, 
atrial fibrillation conferred the highest risk of a future cardiovascular endpoint (3).  QRISK is a 
cardiovascular disease risk calculator, based on a database of anonymised UK primary care patients.  
With an aging population, and a consequent increase in the absolute numbers of individuals having AF, 
any therapy that might prevent the development of AF would be potentially of significant benefit. 
 
Very recently, it has been suggested that N-terminal pro-brain natriuretic peptide (NT-proBNP) is an 
excellent predictor of atrial fibrillation even after adjustment for other known risk factors (4).  A 
different approach was adopted by Framingham Heart Study investigators who recently reported (5) on 
the development of a risk score for atrial fibrillation. This involved various constitutional factors, 
systolic blood pressure, clinically significant heart failure and PR interval among others. 
 
If AF could be reliably predicted, the question arises as to what treatment might be started.  In this 
connection, there is conflicting evidence on the effects of statin therapy. On the one hand, statin 
therapy has recently been reported as being of no value in preventing atrial fibrillation, e.g. in the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (6) while on 
the other hand, in selected situations, statins have been found to be beneficial in preventing AF, e.g. in 
patients with coronary artery disease [7] and after cardiac surgery (8).  This may be related to one of 
the pleiotropic effects of statins, namely being an anti-inflammatory (9) and hence anti-arrhythmic 
agent (10).  However, one recent meta analysis suggested that further trials are required to assess the 
effects of statins on atrial fibrillation (11). 
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The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) aimed to determine whether 
treatment with pravastatin reduces the risk of cardiovascular and cerebrovascular events in elderly 
subjects with vascular disease or at high risk of developing vascular disease (12).  
 
The study showed (13) that pravastatin reduced the incidence of the primary endpoint of coronary 
death, non fatal myocardial infarction and fatal or non fatal stroke [HR 0.85 (0.74-0.97) p=0.014]. 
These effects were mainly due to a reduced incidence of coronary heart disease death and non-fatal 
myocardial infarction, with no reduction seen in stroke risk. 
 
In this further retrospective analysis of the PROSPER dataset, we aimed to determine whether 
pravastatin reduces the incidence of AF and to elucidate risk factors for the development of this 
arrhythmia. This study laid emphasis on electrocardiographic measures of risk but it also reviewed 
baseline data to determine if any clinical risk factors could be identified. .  
 
Methods 
 
The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) recruited 5,504 individuals 
between the ages of 70-82 years with a history of risk factors or established vascular disease (13).  New 
York Heart Association (NYHA) class III/IV heart failure was an exclusion criterion.  2,891 were 
allocated to pravastatin 40mg daily and 2,913 to placebo in a double-blind randomised controlled 
parallel group trial; mean follow-up was 3.2 years.  The study cohort was recruited from the 
Netherlands, Scotland and Southern Ireland. 
 
ECGs were recorded at baseline, annually thereafter and at run out in all participants in the study. It 
was a requirement for entry that individuals should not have AF or flutter. ECG recordings were made 
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using a Burdick Eclipse 850i electrocardiograph and digital data was transmitted from the various 
recording sites to the ECG Core Lab in Glasgow Royal Infirmary. All ECGs were interpreted using the 
same software (14) which provided an interpretation, produced Minnesota Codes (15) and also made 
numerous measurements including the QT interval. A corrected QT interval was also available and the 
first preference was to use the Hodges Formula (16) for QT correction, namely:- 
 
QTc = QT + 1.75 (heart rate - 60). 
 
All ECG measurements used in the study were derived from the baseline ECGs in order to obtain data 
that could be assessed for predictive value.  Information about AF was obtained from annual ECG 
measurements since all baseline ECGs exhibited sinus rhythm. 
   
All the ECGs were reviewed so that if rhythm were to be incorrectly reported by the automated system, 
the corrected interpretation was inserted into the system and the relevant Minnesota Code corrected 
also.  Incident AF was defined as any ECG after baseline showing atrial fibrillation or flutter.  Only the 
first occurrence of the arrhythmia was counted in each individual.  In a few cases, AF was first 
recorded as part of an adverse event. In such cases, the time of this event was used to derive duration 
for time to onset models. 
 
The Minnesota Codes were used to categorise previous myocardial infarction into strongly likely 
(based on Code 1-1), probably present (codes 1-2) or possibly present (codes 1-3). 
 
Lipoprotein profiles were measured at the Core Lab in the CDC Certified Biochemistry Core Lab in 
Glasgow Royal Infirmary.  
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Statistical analysis 
Summary statistics are reported in the Tables as the mean (standard deviation [SD]) for continuous 
variables and number (%) for categorical variables. Positively skewed variables (triglycerides) were log 
transformed. Baseline characteristics and baseline ECG variables were compared between participants 
who did and did not develop AF during the study using the unpaired two-sample t-test for continuous 
variables and the chi-squared test for categorical variables. The effect of pravastatin on development of 
AF was investigated by the Kaplan-Meier method and statistical significance assessed by the log-rank 
test. Associations between baseline ECG characteristics and development of AF were examined using 
Cox proportional hazards models, adjusting for randomized treatment and baseline covariates (age, sex, 
country, diabetes, use of anti-hypertension medication, smoking, systolic and diastolic blood pressure, 
low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, triglycerides, body mass 
index, alcohol consumption, history of coronary disease, history of cerebrovascular disease, history of 
peripheral arterial disease and heart rate). Validity of the proportional hazards assumption was assessed 
by testing the significance of interaction terms between ECG variables and the logarithm of time as a 
time dependent covariate. Results are reported, where appropriate, as hazard ratios with 95% 
confidence intervals and corresponding p-value. For continuous ECG variables (such as heart rate), the 
stated hazard ratio (HR) represents an increase of approximately 1 SD and for categorical variables, 
such as definite left ventricular hypertrophy (LVH), a change from No to Yes. A p-value of <0.05 was 
considered statistically significant.  
 
 
Results 
A total of 547 (9.4%) subjects developed AF (521 persons) or atrial flutter (26 persons) during the 
course of the study.  Four individuals appeared to have AF on entry and had to be excluded from the 
analysis. Figure 1 shows that pravastatin had no effect on the cumulative incidence of AF.  264/2912 
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(9.1%) of the placebo group and 283/2888 (9.8%) of the pravastatin treated group developed AF [HR 
1.08 (0.92-1.28) p=0.35].  
 
Table 1 compares the baseline characteristics of those who did and those did not develop AF during the 
course of the study. It can be seen that in those who developed AF, age was on average about 7 months 
older, total and LDL cholesterol was marginally though statistically significantly lower, subjects were 
more likely to be male and were more likely to have a history of any vascular disease compared to 
those who did not develop AF.  Alcohol consumption was very significantly higher in those who 
developed AF.  Diabetes, hypertension (implying an individual was on treatment) and previous 
stroke/transient ischemic attack (TIA) were not risk factors for the development of AF - nor was being 
a current smoker (p=0.057).  Table 2 lists the baseline anti-hypertensive medications for the statin 
treated and the placebo groups, separately and together.  Additional adjustments were made for 
treatment with an ACE inhibitor and for each other blood pressure lowering treatment with no 
difference in the results. 
 
With respect to some specific ECG findings, Table 3 shows a similar comparison between the two 
groups. QRS duration, corrected and uncorrected QT interval, as well as PR interval were statistically 
significantly longer in the group that developed AF. Interestingly, the P wave duration was also 
significantly longer in this group but the mean difference between groups of 2 ms is of no clinical 
significance.  
 
The association between baseline characteristics and the risk of AF is shown in Table 4.  The risks are 
shown for individual measures using different models. The first adjusted for treatment allocation only, 
the second adjusted in addition for age, sex, country, diabetes, alcohol consumption etc while the third 
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adjusted for vascular disease and heart rate in addition.  Table 4 shows that age, corrected QT interval 
and PR interval were all strongly associated with increased risk of developing AF.   
 
Other electrocardiographic markers of previous myocardial infarction and LVH were also studied. 
Table 4 shows that, although each of the three categories of myocardial infarction was strongly 
associated with the development of AF using the unadjusted model, the link disappeared after 
adjustment for other factors, as previously described.   
 
Minnesota codes were also used to definite, probable and possible LVH.  Evidence of very high QRS 
voltage plus ST-T changes defined definite LVH, less high though abnormal QRS voltage plus ST-T 
changes defined probable LVH while very high voltage only defined possible LVH.  In all cases, as 
shown in Table 3, there was a significant relationship between the presence of LVH and the risk of AF. 
This was particularly true for definite or probable LVH where there was over a twofold increase in risk 
of developing AF in subjects in these categories. 
 
ST-T changes based on Minnesota Codes 4-1 to 4-3 and 5-1 to 5-3 were also assessed independently of 
QRS voltage.  Marked changes, i.e. 5-1 or 5-2 as well as 4-1 or 4-2 conferred a significantly increased 
risk of AF of approximately 70% (see Table 3).  Even what might be termed minor ST-T changes, 
namely the presence of minimal ST depression (4-3) and T wave flattening or inversion (5-3) conferred 
an increased risk of 29% though this was not statistically significant.  
 
Discussion 
This study has shown that the administration of pravastatin 40mg per diem had no effect (p = 0.35) on 
the prevention of AF in an elderly group of individuals aged over 70 years who were followed for a 
mean of 3.2 years.  It might be suggested that the treatment period was not long enough to show any 
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benefit but Figure 1 demonstrates that at the end of 3 years, there was a very similar incidence of AF in 
the treated and untreated groups with no suggestion of a trend in favour of either group that might have 
continued to significance in a longer study.  Although there have been differing outcomes in the use of 
statins to prevent AF, this study is one of the largest of its kind in an age group where the incidence of 
AF is relatively high. Indeed, the study again showed that age itself is a significant risk factor for AF 
despite the narrow age range of those in the study cohort. 
 
Although pravastatin reduced the risk of coronary events over a 3.2 year period, the time-span may not 
have been sufficient for the downstream consequences of cardiac damage, such as atrial fibrillation, to 
become evident. Alternatively it could be that pravastatin genuinely does not give protection against 
new onset AF, which in many older patients is likely to be a multifactorial arrhythmia, not  due to 
ischaemic heart disease alone (17).    
 
It might be argued that a different statin might have produced a different result but the only way that 
such a hypothesis could be tested would be to have run a much larger, and perhaps longer, trial with 
participants randomized to different statins to determine if there was any difference in incident AF.  
 
Approximately 9% of this age group developed  AF in a three year period in an almost linear fashion 
which suggests that the annual incidence of AF is approximately 3% per annum in the over 70 age 
group.  This emphasizes the treatment burden that will arise as the number of individuals in this age 
group increases in the coming years. 
 
Results are based on a single 10 second ECG recording made at an annual trial review and all ECGs 
were carefully reviewed centrally in the ECG core lab at Glasgow Royal Infirmary to ensure 
consistency of interpretation.  Paroxysmal AF may have been grossly under-diagnosed from an annual 
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ECG but the converse of the 10 sec recording being obtained at the time of a paroxysm is much more 
unlikely.   
 
It was not unexpected that increased P wave duration might be linked to the development of AF as this 
has been noted previously particularly using the signal averaged ECG (18). It could be argued that the 
increased P duration is due to the increased time for atrial activation to occur in what might be an 
overstretched left atrium.  However, the clinical utility of this finding is limited in the context of a very 
small difference of 2 ms between the mean P values in each group.  The result might imply that if serial 
ECGs were to be recorded in individuals and P wave duration tracked, some trend in P duration might 
be noted but the accuracy of automated P wave duration is not high with acceptable errors being the 
order of 20 ms (19). Furthermore, in the multivariate analysis, the contribution of the P wave was not 
significant. 
 
In contrast, increased PR interval and QTc interval were linked with the development of AF.  The link 
with PR interval confirms what was recently noted in the Framingham study cohort (5) and also in a 
group of cross country skiers (20) but to the best of our knowledge, the association of increasing QT 
interval with the development of AF has not previously been reported.  The respective mean 
differences of approximately 5ms in PR interval and 7ms in QTc interval between those who do and 
those who do not develop AF are again of little clinical value but the 27% and 21% increase in risk 
associated with an increased PR and QTc suggest that more notice should be taken of ECGs showing 
an abnormal PR interval and/or abnormal QTc in this age group.  A prolonged QTc has for some time 
been associated with arrhythmogenesis and, for example, sudden death in an elderly population (21) 
but AF is not generally regarded as being linked with this phenomenon.   
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LVH with ST-T changes has previously been linked with an adverse prognosis.  In the Framingham 
study, ECG LVH carried a risk as great as previous myocardial infarction (22).  An increased P 
terminal force (amplitude x duration of the negative component of P in V1) is in itself used as a 
criterion for LVH (23).  Thus, LVH is linked with left atrial enlargement and hence a propensity to 
develop AF.  
 
Marked ST-T changes were also linked to AF but in turn they can be linked to LVH and/or ischemic 
heart disease both of which would be regarded as precursors of AF. 
 
It is important to note that those ECG measures regarded as risk factors for AF emerged after 
allowance for other factors that were also strongly implicated in the development of AF, namely age, 
alcohol consumption, and a history of vascular disease.   
 
It might be conjectured that those with definite LVH, prolonged PR interval > 0.20ms and QTc > 
0.46ms would be at high risk of developing AF but there were only two such individuals who met these 
criteria so there was no possibility of testing this simple model in a meaningful way. 
 
There were some limitations to the study. First of all, the relatively short mean duration of 3.2 years 
follow up may have mitigated against pravastatin having an effect on the development of AF.  It might 
also be that in this age group, structural changes in the myocardium are the main risk factor which 
cannot be influenced by any drug therapy. 
 
Because of the design structure of the trial, the recruitment of more subjects with hypertension, history 
of smoking and diabetes, (and more women) into the low risk primary prevention group could have 
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potentially been misleading in terms of the significance or non-significance of univariate comparisons, 
and hence they were corrected for in the analysis. 
 
In conclusion, this study has shown that the use of pravastatin in an elderly population at risk of 
developing AF did not have any effect on the incidence of this arrhythmia, at least in the short term.  
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LEGEND 
 
Figure 1.   Cumulative incidence of Atrial Fibrillation in subjects allocated to Pravastatin compared to 
placebo. There was no significant difference between treatment groups [log-rank p = 0.35, HR 1.08 
(0.92-1.28)]. 
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Figure 1.  
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 Table 1.  Comparison of baseline characteristics in PROSPER subjects who developed atrial 
fibrillation/flutter (AF) versus those who did not develop this arrhythmia. 
 AF 
(n=547) 
No AF 
 (n=5253) 
P-value 
 
Continuous variables, mean(SD)    
Age (years)   75.9 (3.5)    75.3 (3.3) <0.0001 
Body mass index (kg/m
2
)   27.2 (4.3)    26.8 (4.2)   0.038 
Systolic blood pressure (mmHg) 155.8 (22.1)  154.5 (21.8)   0.19 
Diastolic blood pressure (mmHg)   83.5 (12.0)    83.8 (11.4)   0.52 
Total cholesterol (mmol/l)    5.56 (0.89)     5.69 (0.91)   0.0014 
HDL cholesterol (mmol/l)    1.27 (0.35)     1.28 (0.35)   0.42 
LDL cholesterol (mmol/l)    3.69 (0.82)     3.80 (0.80)   0.0015 
Triglycerides (mmol/l)*    1.39 (1.56)     1.41 (1.51)   0.41 
Alcohol units per week    6.90 (12.2)     5.04 (8.93)  <0.0001 
Categorical variables, n (%)    
Male 318 (58.1) 2483 (47.3) <0.0001 
Smoking 
 Never                                    
 Current smoker   
 Ex smoker 
 
184 (33.6) 
128 (23.4) 
235 (43.0) 
 
1783 (33.9) 
1429 (27.2) 
2041 (38.9) 
  0.090 
Country 
   Scotland 
    Ireland 
    Netherlands 
 
228 (41.7) 
228 (41.7) 
  91 (16.6) 
 
2291 (43.6) 
1953 (37.2) 
1009 (19.2) 
  0.090 
History of:    
  Diabetes   63 (11.5)    559 (10.6)   0.53 
  Hypertension 354 (64.7) 3234  (61.6)   0.15 
  Coronary disease 204 (37.3) 1641 (31.2)   0.0038 
  Peripheral arterial disease   76 (13.9)   573 (10.9)   0.035 
  Stroke or TIA   68 (12.4)   580 (11.0)   0.33 
  Any vascular disease 286  (52.3)   261 (47.7) <0.0001 
TIA: transient ischemic attack.   
All available data used.  
P-values for continuous variables are from two-sample t-test and for categorical variables from chi-squared test.  
* Values are geometric means (SD) calculated from the log-transformed distribution.  
Table
 2 
  
 
Table 2.  Baseline anti-hypertensive medications for the PROSPER cohort split by treatment 
allocation, and for the group as a whole. 
 
 
Medication at baseline Placebo (n=2912) Pravastatin 
(n=2888) 
Both groups 
(n=5800) 
ACE-inhibitors 469 (16.1%) 480 (16.6%) 949 (16.4%) 
Diuretic 1183 (40.6%) 1171 (40.5%) 2354 (40.6%) 
All receptor 
antagonists 
48 (1.6%) 68 (2.4%) 116 (2.0%) 
Beta Blocker 764 (26.2%) 737 (25.5%) 1501 (25.9%) 
Calcium Channel 
blocker 
704 (24.2%) 754 (26.1%) 1458 (25.1%) 
Other 
antihypertensive 
122 (4.2%) 115 (4.0%) 237 (4.1%) 
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Table 3.  Comparison of baseline ECG measurements in PROSPER subjects who developed atrial 
fibrillation/flutter (AF) versus those who did not develop this arrhythmia. 
 AF   No AF P-value 
 
Continuous variables  
(N, mean (SD)) 
     
Heart rate (bpm) 540    65.8 (12.0) 5140   66.4 (11.6)   0.29 
QRS duration (ms) 540    97.5 (19.6) 5139   94.5 (19.0)   0.0005 
QT interval (ms) 540 420.2  (39.8) 5140 411.9 (37.1) <0.0001 
QTc interval (ms) 540 430.4 (28.8) 5140 423.0 (27.1) <0.0001 
PR interval (ms) 513 169.4 (30.7)  5038 164.2 (27.7) <0.0001 
P wave duration (ms) 507 111.2 (19.5) 4956 109.6 (16.0)   0.028 
Continuous variables  
(N, n (%)) 
     
Previous Myocardial Infarction      
Strong evidence  
(Minnesota code 1-1-x) 
540   49 (9.1) 5140 330 (6.4)   0.019 
Less Strong evidence 
(Minnesota codes 1-1-x or 1-2-x) 
540   76 (14.1) 5140 526 (10.2)   0.0058 
Weak evidence 
(Minnesota codes 1-1-x or 1-2-x or 
1-3-x) 
540 123 (22.8) 5140 942 (18.3)   0.012 
Left ventricular hypertrophy (LVH)      
(a) Definite LVH 540   22 (4.1) 5140   95 (1.8)   0.0005 
(b) Probable LVH 540   27 (5.0) 5140 111 (2.2) <0.0001 
(c) Possible LVH 540   87 (16.1) 5140 622 (12.1)   0.0073 
Non Specific ST changes      
Minnesota code 5-1 540     1 (0.2) 5140   28 (0.5)   0.52* 
Minnesota code 5-1 plus (any code 
4) 
540     1 (0.2) 5140   28 (0.5)   0.52* 
Minnesota code 5-1 or 5-2 540   91 (16.8) 5140 531 (10.3) <0.0001 
Minnesota code (5-1 or 5-2) plus 
(any code 4) 
540   81 (15.0) 5140 475 (9.2) <0.0001 
Minnesota code 4-1 or 4-2 540   70 (13.0) 5140 381 (7.4) <0.0001 
Minnesota code 4-3 plus code 5-3 540   56 (10.4) 5140 418 (8.1)   0.074 
P-values for continuous variables are from two-sample t-test and for categorical variables from chi-squared test.  
* Fisher Exact Test. 
(a) Minnesota Codes 3-1 plus (4-1 or 4-2 lateral) plus (5-1 or 5-2 lateral). 
(b) (a) or Minnesota Codes 3-3 plus (4-1 or 4-2 lateral) plus (5-1 or 5-2 lateral). 
(c) (a) or (b) or Minnesota Codes 3-1. 
 4 
 
Table 4. Association between baseline age, heart rate and ECG characteristics, and risk of incident 
atrial fibrillation/flutter 
 
 Model 1* Model 2
†
 Model 3
‡
 
Hazard Ratio 
(95% CI) 
P-value Hazard Ratio 
(95% CI) 
P-value Hazard Ratio 
(95% CI) 
P-value 
Continuous variables       
Age (5 years) 1.35 (1.20, 1.53) <0.0001 1.38 (1.22, 1.57) <0.0001 1.38 (1.21, 1.57)  <0.0001 
Heart rate (10 bpm) 0.98 (0.91, 1.05)   0.98 1.00 (0.92, 1.07)   0.90 0.99 (0.92, 1.07)   0.82 
QRS duration (20ms) 1.17 (1.08,1.27) <0.0001 1.05(0.97, 1.15)   0.23 1.07 (0.98, 1.16)   0.14 
QT interval (40ms) 1.24 (1.14, 1.35) <0.0001 1.20 (1.10, 1.31) <0.0001 1.41 (1.25, 1.58)  <0.0001 
QTc interval (30 ms) 1.31 (1.20, 1.42) <0.0001 1.27 (1.16, 1.38) <0.0001 1.21 (1.11, 1.32) <0.0001 
PR interval (30ms) 1.19 (1.09, 1.30),  <0.0001 1.11 (1.01, 1.21)   0.027 1.29 (1.18, 1.41) <0.0001 
P wave duration (20ms) 
 
1.14 (1.02, 1.27)   0.022 1.07 (0.96, 1.19)   0.26  1.08 (0.96, 1.20)   0.20 
Categorical variables        
Previous MI       
Strong evidence  
(Minnesota code 1-1-x) 
1.51 (1.12, 2.02) 0.0061 1.12 (0.82, 1.52) 0.49 1.22 (0.90, 1.65)   0.19 
Less Strong evidence 
(Minnesota codes 1-1-x or 
1-2-x) 
1.46 (1.15, 1.86) 0.0021 1.13 (0.87, 1.46) 0.37 1.23 (0.58, 1.58)   0.11 
Weak evidence 
(Minnesota codes 1-1-x or 
1-2-x or 1-3-x) 
1.33 (1.09, 1.63) 0.0055 1.09 (0.88, 1.35) 0.43 1.17 (0.95, 1.44)   0.14 
LVH       
(a) Definite LVH 2.20 (1.44, 3.37) 0.0003 2.05 (1.33, 3.15) 0.0011 2.13 (1.38, 3.28)   0.0006 
(b) Probable LVH 2.33 (1.58, 3.44) <0.0001 2.14 (1.45, 3.17) 0.0001 2.21 (1.49, 3.28)  <0.0001 
(c) Possible LVH 1.35 (1.08, 1.70) 0.010 1.29 (1.02, 1.63) 0.033 1.30 (1.03, 1.64)   0.028 
Non Specific ST changes       
Minnesota code 5-1 0.34 (0.05, 2.43) 0.28 0.40 (0.06, 2.87) 0.37 0.39 (0.05, 2.76)   0.34 
Minnesota code 5-1 plus 
(any code 4) 
0.34 (0.05, 2.43) 0.28 0.40 (0.06, 2.87) 0.37 0.39 (0.05, 2.76)   0.34 
Minnesota code 5-1 or 5-2 1.76 (1.41, 2.21) <0.0001 1.62 (1.28, 2.04) <0.0001 1.69 (1.34, 2.13) <0.0001 
Minnesota code (5-1 or 5-
2) plus (any code 4) 
1.72 (1.36, 2.18) <0.0001 1.58 (1.24, 2.00)  0.0002 1.64 (1.29, 2.09)   0.0001 
Minnesota code 4-1 or 4-2 1.85 (1.44, 2.38) <0.0001 1.68 (1.30, 2.16) <0.0001 1.70 (1.32, 2.20) <0.0001 
Minnesota code 4-3 plus 
code 5-3 
1.34 (1.01, 1.76) 0.040 1.33 (1.00, 1.76)   0.047 1.35 (1.02, 1.78)   0.037 
Hazard ratios and confidence intervals are for increases of units specified in brackets for continuous measures, i.e. for age 
increase of 5 years.  
*Adjusted for treatment allocation only. 
†
Adjusted for treatment allocation, age, sex, country, diabetes, use of anti-hypertension medication, smoking, systolic and 
diastolic blood pressure, LDL and HDL cholesterol, triglycerides, body mass index and alcohol consumption. 
‡
 In addition adjusted for history of coronary disease, history of cerebrovascular disease, history of peripheral arterial 
disease and heart rate. 
(a) Minnesota Codes 3-1 plus (4-1 or 4-2 lateral) plus (5-1 or 5-2 lateral). 
(b) (a) or Minnesota Codes 3-3 plus (4-1 or 4-2 lateral) plus (5-1 or 5-2 lateral). 
(c) (a) or (b) or Minnesota Codes 3-1.
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